# US 6,730,511 B1 · Vectors that repress heterologous promoter activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,511 B1
- Document ID: US6730511B1
- Status: Granted
- Kind: B1
- Application number: 08/925,214
- Filed: 1997-09-08
- Granted: 2004-05-04
- Earliest claimed: 1995-03-09
- Assignees: GSF-Forschungszentrum Fuer Umwelt und Gesendheit GmbH
- Inventors: Walter H. Günzburg; Brian Salmons
- Web page: https://patentgrep.com/patent/US6730511B1

## CPC

- C12N 15/86: Viral vectors
- A61K 38/162: {from virus}
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61P 35/00: Antineoplastic agents
- C07K 14/005: from viruses
- C12N 2740/13022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2740/13043: viral genome or elements thereof as genetic vector
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention refers to a novel recombinant vectors useful for gene therapy of viral infections and of diseases associated with B and T cells. The present invention relates, furthermore, to novel usages of the two products of the open reading frame of mouse mammary tumour virus.

## Claims

### Claim 1

A recombinant vector comprising, mouse mammary tumor virus sequences which consist of a mouse mammary tumor virus long terminal repeat open reading frame and a naf activity sequence, wherein said naf activity sequence is between an R region of a 5′ long terminal repeat and a 3′ end of a gag gene of the mouse mammary tumor virus thereby including a splice donor site which is in addition to the splice donor site at the 5′ end of the gag gene, and wherein the remainder of the vector is derived from a vector other than a mouse mammary tumor virus.

### Claim 2 (depends on 1)

An isolated RNA of the vector according to claim 1.

### Claim 3 (depends on 1)

An isolated host cell comprising the vector according to claim 1.

### Claim 4 (depends on 1)

A method of producing a host cell having an MMTV-LTR ORF and a sequence of an MMTV gag gene with naf activity comprising transfecting the host cell with the vector of claim 1.

### Claim 5 (depends on 4)

A host cell produced by the method of claim 4.

### Claim 6 (depends on 1)

A method for repressing the activity of a viral promoter other than a mouse mammary tumor viral promoter, comprising transducing a target cell comprising said promoter with the vector according to claim 1, wherein the viral promoter is repressed.

### Claim 7 (depends on 1)

The recombinant vector according to claim 1, wherein said vector is a vector selected from the group consisting of: RNA virus vectors, DNA virus vectors and eucaryotic expression vectors.

### Claim 8 (depends on 7)

A recombinant vector according to claim 7, wherein said vector is selected from the group consisting of: adenovirus vectors, adenovirus associated virus a vectors, herpes virus vectors and retrovirus vectors.

### Claim 9 (depends on 8)

A recombinant retroviral vector system which is capable of producing a retroviral particle, comprising a retroviral vector according to claim 8 wherein the retroviral vector is replication defective and a packaging cell line comprising a retroviral or recombinant retroviral construct coding for proteins required for packaging a product transcribed from said retroviral vector.

### Claim 10 (depends on 9)

An isolated retroviral particle produced by the retroviral vector system of claim 9.

### Claim 11 (depends on 10)

A recombinant retroviral provirus produced by infecting a target cell with the retroviral particle of claim 10.

### Claim 12 (depends on 11)

An isolated mRNA transcribed from a retroviral provirus according to claim 11.

### Claim 13 (depends on 10)

A method of producing a host cell having an MMTV-LTR ORF and a sequence of an MMTV gag gene with naf activity comprising infecting the host cell with the retroviral particle of claim 10.

### Claim 14 (depends on 13)

A host cell produced by the method of claim 13.

### Claim 15 (depends on 10)

A method for repressing the activity of a viral promoter comprising other than a mouse mammary tumor viral promoter, infecting a target cell comprising said promoter with the retroviral particle of claim 10, wherein the viral promoter is repressed.

### Claim 16 (depends on 10)

A method for introducing nucleotide sequences which encode Naf into a cell comprising infecting said cell with the retroviral particle of claim 10 and culturing the cell under conditions in which naf is expressed in said cell, thereby introducing nucleotide sequences which encode Naf into a cell.

### Claim 17 (depends on 16)

The method of claim 16 wherein the cell is selected from the group consisting of: an animal cell and a human cell.

### Claim 18

A recombinant retroviral vector which is capable of undergoing promoter conversion and is replication-defective comprising, in operable linkage,
a) a 5′ long terminal repeat region comprising the structure U3-R-U5 site, derived from a vector other than a mouse mammary tumor virus;
b) mouse mammary tumor virus sequences consisting of an open reading frame having naf activity derived from a mouse mammary tumor virus long terminal repeat and a naf activity sequence, wherein said naf activity sequence is between an R region of a 5′ long terminal repeat and a 3′ end of a gag gene of the mouse mammary tumor virus thereby including a splice donor site which is in addition to the splice donor site at the 5′ end of the gag gene;
c) optionally, at least one sequence encoding a peptide selected from the group consisting of: β-galactosidase, neomycin, alcohol dehydrogenase, puromycin, hypoxanthine phosphoribosyl transferase (HPRT), hygromycin, secreted alkaline phosphatase, Herpes Simplex Virus thymidine kinase, cytosine deaminase, guanine phosphoribosyl transferase (gpt), cytochrome P 450, cell cycle regulatory proteins, tumor suppressor proteins, antiproliferation proteins, and cytokines; and
d) a 3′ long terminal repeat region derived from a vector other than a mouse mammary tumor virus comprising a completely or partially deleted U3 region wherein said deleted U3 region is replaced by a polylinker sequence carrying at least one unique restriction site.

### Claim 19 (depends on 18)

The recombinant vector of claim 18 wherein one or more heterologous DNA fragments are inserted into said polylinker sequence, followed by the R and U5 region.

### Claim 20 (depends on 19)

The recombinant vector according to claim 19 wherein said heterologous DNA fragment comprises at least one non-coding sequence selected from regulatory elements or promoters which regulate the expression of at least one of the coding sequences of said recombinant vector.

### Claim 21

A mouse mammary tumor virus vector comprising a mouse mammary tumor virus long terminal repeat open reading frame, a naf activity sequence, wherein said naf activity sequence consists of a sequence of the mouse tumor virus which is between an R region of a 5′ long terminal repeat and a 3′ end of a gag gene of the mouse mammary tumor virus thereby including a splice donor site which is in addition to the splice donor site at the 5′ end of the gag gene and non-functional mouse mammary tumor virus pol and env genes.

### Claim 22 (depends on 21)

The vector according to claim 21, wherein the pol and env genes are mutated or wholly or partially deleted so that the pol and env genes are nonfunctional.

### Claim 23 (depends on 21)

An isolated RNA of the vector according to claim 21.

### Claim 24 (depends on 21)

An isolated host cell comprising the vector according to claim 21.

### Claim 25 (depends on 21)

A method of producing a host cell having an MMTV-LTR ORF, a sequence of an MMTV gag gene with naf activity, and non-functional MMTV pol and env genes comprising transfecting the host cell with the vector of claim 21.

### Claim 26 (depends on 25)

A host cell produced by the method of claim 25.

### Claim 27 (depends on 21)

A method for repressing the activity of a viral promoter other than a mouse mammary tumor viral promoter comprising transducing a target cell comprising said promoter with the vector according to claim 21, wherein the viral promoter is repressed.

### Claim 28 (depends on 21)

A recombinant retroviral vector system which is capable of producing a retroviral particle, comprising a retroviral vector according to claim 21 wherein the retroviral vector is replication deficient and a packaging cell line including a retroviral or recombinant retroviral construct coding for proteins required for packaging of a product transcribed from said retroviral vector.

### Claim 29 (depends on 28)

An isolated retroviral particle produced by the retroviral vector system of claim 28.

### Claim 30 (depends on 29)

A recombinant retroviral provirus produced by infecting a target cell with the retroviral particle of claim 29.

### Claim 31 (depends on 30)

An isolated mRNA transcribed from a retroviral provirus according to claim 30.

### Claim 32 (depends on 29)

A method of producing a host cell having an MMTV-LTR ORF, a sequence of an MMTV gag gene with naf activity, and non-functional MMTV pol and env genes comprising infecting the host cell with the retroviral particle of claim 29.

### Claim 33 (depends on 32)

A host cell produced by the method of claim 32.

### Claim 34 (depends on 29)

A method for repressing the activity of a viral promoter other than a mouse mammary tumor viral promoter comprising infecting a target cell comprising said promoter with the retroviral particle of claim 29, wherein the viral promoter is repressed.

### Claim 35 (depends on 29)

A method for introducing nucleotide sequences which encode Naf into a cell comprising infecting said cell with the retroviral particle of claim 29 and culturing the cells under conditions in which naf is expressed in said cell, thereby introducing nucleotide sequences which encode Naf activity into a cell.

### Claim 36

A mouse mammary tumor virus recombinant retroviral vector which is capable of undergoing promoter conversion and is replication-defective comprising, in operable linkage,
a) a 5′ long terminal repeat region comprising the structure U3-R-U5, derived from a vector other than a mouse mammary tumor virus;
b) mouse mammary tumor virus sequences consisting of an open reading frame having naf activity derived from a mouse mammary tumor virus long terminal repeat, a naf activity sequence wherein said naf activity sequence is between an R region of a 5′ long terminal repeat and a 3′ end of the gag gene of the mouse mammary tumor virus thereby including a splice donor site which is in addition to the splice donor site at the 5′ end of the gag gene, and non-functional mouse mammary tumor virus pol and env genes;
c) optionally, at least one sequence encoding a peptide selected from the group consisting of: β-galactosidase, neomycin, alcohol dehydrogenase, puromycin, hypoxanthine phosphoribosyl transferase (HPRT), hygromycin, secreted alkaline phosphatase, Herpes Simplex Virus thymidine kinase, cytosine deaminase, guanine phosphoribosyl transferase (gpt), cytochrome P 450, cell cycle regulatory proteins, tumor suppressor proteins, antiproliferation proteins, and cytokines; and
d) a 3′ long terminal repeat region derived from a vector other than a mouse mammary tumor virus comprising a completely or partially deleted U3 region wherein said deleted U3 region is replaced by a polylinker sequence carrying at least one unique restriction site.

### Claim 37 (depends on 36)

The recombinant vector of claim 36 wherein one or more heterologous DNA fragments are inserted into said polylinker sequence, followed by the R and U5 region.

### Claim 38 (depends on 37)

The recombinant vector according to claim 37 wherein said heterologous DNA fragment comprises at least one non-coding sequence selected from regulatory elements or promoters which regulate the expression of at least one of the coding sequences of said recombinant vector.

### Claim 39

An isolated host cell comprising an MMTV-LTR ORF and a sequence of an MMTV gag gene with naf activity, said sequences being introduced by a non-MMTV construct into said host cell, wherein the non-MMTV construct comprises MMTV sequences which consist of the MMTV-LTR ORF and a naf activity sequence, wherein said naf activity sequence is between an R region of a 5′ long terminal repeat and a 3′ end of a gag gene of the mouse mammary tumor virus thereby including a splice donor site which is in addition to the splice donor site at the 5′ end of the gag gene.

### Claim 40

An isolated host cell comprising an MMTV-LTR ORF, a sequence of an MMTV gag gene with naf activity, and non-functional MMTV pol and env genes.

### Claim 41

A method for repressing activity of a viral promoter other than a MMTV promoter in cells in which said viral promoter is present, comprising
a). introducing a MMTV naf activity sequence into the cells wherein the naf activity sequence consists of a mouse mammary tumor virus long terminal repeat open reading frame and a gag gene of a mouse mammary tumor virus, and said gag sequence is between an R region of a 5′ long terminal repeat and a 3′ end of the gag gene of the mouse mammary tumor virus; and
b). maintaining the cells under conditions in which the naf sequence is expressed, thereby repressing activity of the viral promoter,
wherein the viral promoter is repressed by a naf activity sequence,.

### Claim 42 (depends on 41)

The method according to claim 41, wherein the naf sequence is introduced via a vector, said vector is a vector selected from the group consisting of: RNA virus vectors, DNA virus vectors and eucaryotic expression vectors.

### Claim 43 (depends on 42)

The method according to claim 42, wherein said vector is selected from the group consisting of: adenovirus vectors, adenovirus associated virus vectors, herpes virus vectors and retrovirus vectors.

### Claim 44 (depends on 41)

The method of claim 41 wherein the viral promoter is selected from the group consisting of: an HIV promoter, a MLV promoter and a HSVtk promoter.
